Article
Clinical Neurology
Chao Zhu, Zhen Zhou, Izanne Roos, Daniel Merlo, Tomas Kalincik, Serkan Ozakbas, Olga Skibina, Jens Kuhle, Suzanne Hodgkinson, Cavit Boz, Raed Alroughani, Jeannette Lechner-Scott, Michael Barnett, Guillermo Izquierdo, Alexandre Prat, Dana Horakova, Eva Kubala Havrdova, Richard Macdonell, Francesco Patti, Samia Joseph Khoury, Mark Slee, Rana Karabudak, Marco Onofrj, Vincent Van Pesch, Julie Prevost, Mastura Monif, Vilija Jokubaitis, Anneke van der Walt, Helmut Butzkueven
Summary: Ocrelizumab and natalizumab are more effective than cladribine in reducing relapses in patients with relapsing-remitting multiple sclerosis switching from fingolimod. Additional observation time is needed to determine if the statistical difference in annualized relapse rate (ARR) results in long-term disability differences.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2022)
Article
Clinical Neurology
Kevin Bigaut, Laurent Kremer, Thibaut Fabacher, Guido Ahle, Mathilde Goudot, Marie Fleury, Claude Gaultier, Sylvie Courtois, Nicolas Collongues, Jerome de Seze
Summary: This study compared the effectiveness of ocrelizumab and fingolimod after natalizumab cessation. The results showed that ocrelizumab had a significantly lower relapse rate at 1 year compared to fingolimod.
JOURNAL OF NEUROLOGY
(2022)
Article
Clinical Neurology
Ruggero Capra, Vincenzo Brescia Morra, Massimiliano Mirabella, Claudio Gasperini, Cinzia Scandellari, Rocco Totaro, Nicola De Rossi, Silvia Masera, Valentina Zipoli, Francesco Patti
Summary: The WANT study evaluated work ability, quality of life, and cognitive processing speed in Natalizumab-treated MS patients, showing improvements in work productivity and quality of life after one year of treatment, with an adverse event rate of 30.8%.
NEUROLOGICAL SCIENCES
(2021)
Article
Clinical Neurology
Alyssa A. Toorop, Zoe L. E. van Kempen, Maurice Steenhuis, Jessica Nielsen, L. G. F. Sinnige, Gert van Dijk, Christiaan M. Roosendaal, Edo P. J. Arnoldus, Elske Hoitsma, Birgit Lissenberg-Witte, Brigit A. de Jong, Bob W. van Oosten, Eva M. M. Strijbis, Bernard M. J. Uitdehaag, Theo Rispens, Joep Killestein
Summary: The study evaluated the change in natalizumab trough drug levels when switching from intravenous to subcutaneous administration. It was found that the drug levels were on average 55% lower with subcutaneous administration, leading to very low levels in some patients. Monitoring of trough drug levels is advised when switching to subcutaneous administration in patients with low intravenous drug levels, higher body mass index, or extended treatment intervals.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2023)
Review
Medicine, General & Internal
Klaudia Sapko, Anna Jamroz-Wisniewska, Konrad Rejdak
Summary: Multiple sclerosis (MS) is an inflammatory, demyelinating disease of the central nervous system. The pathogenesis of progressive MS (PMS) is complex and causes therapeutic difficulties. The efficacy of currently available anti-inflammatory drugs for PMS is limited in time. In search of innovative solutions, several research studies have evaluated the effectiveness of drugs with neuroprotective or remyelinating effects in PMS. This review discusses the compounds that have entered the clinical assessment phase and explores future prospects for successful PMS treatment.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Virology
Simone Agostini, Roberta Mancuso, Andrea Saul Costa, Domenico Caputo, Mario Clerici
Summary: The detection of miR-J1-5p in urine of MS patients treated with Natalizumab could potentially serve as a biomarker to monitor JCPyV infection and better identify the risk of developing PML. The study found miR-J1-5p in the urine of 28% of patients, even in some cases where JCPyV DNA was not detected in urine or blood. This suggests that miR-J1-5p measurement could be valuable in assessing PML risk in Natalizumab-treated MS patients.
Article
Medicine, General & Internal
Ranjani Ganapathy Subramanian, Dana Horakova, Manuela Vaneckova, Balazs Lorincz, Jan Krasensky, Eva Kubala Havrdova, Tomas Uher
Summary: The study found that natalizumab treatment can reduce inflammatory markers in the cerebrospinal fluid of multiple sclerosis patients, decrease the levels of white blood cells and proteins, as well as the number of oligoclonal bands in the cerebrospinal fluid. Additionally, the baseline IgM index was found to predict brain volume loss during natalizumab treatment.
Article
Clinical Neurology
Marco Puthenparampil, Marta Gaggiola, Alessandro Miscioscia, Valentina Annamaria Mauceri, Federica De Napoli, Giovanni Zanotelli, Mariagiulia Anglani, Margherita Nosadini, Stefano Sartori, Paola Perini, Francesca Rinaldi, Paolo Gallo
Summary: This study evaluated the efficacy and safety of alemtuzumab (ALZ) in pediatric-onset multiple sclerosis (POMS) and adult-onset multiple sclerosis (AOMS) patients undergoing treatment switch. The results showed that ALZ was more effective in AOMS patients compared to POMS patients after switching from natalizumab (NTZ). However, these findings may underestimate the effectiveness of ALZ in POMS patients.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS
(2023)
Article
Clinical Neurology
Alyssa A. Toorop, Zoe Y. G. J. van Lierop, Liza M. Y. Gelissen, Elske Hoitsma, Esther M. P. E. Zeinstra, Luuk C. van Rooij, Caspar E. P. van Munster, Anke Vennegoor, Jop P. Mostert, Beatrijs H. A. Wokke, Nynke F. Kalkers, Erwin L. J. Hoogervorst, Jeroen J. J. van Eijk, Christiaan M. Roosendaal, Jolijn J. Kragt, Marijke Eurelings, Jessie van Genugten, Jessica Nielsen, Lgf Sinnige, Mark E. Kloosterziel, Edo P. J. Arnoldus, Gert W. van Dijk, Willem H. Bouvy, Mark H. J. Wessels, Lynn Boonkamp, Eva M. M. Strijbis, Bob W. van Oosten, Brigit A. De Jong, Birgit Lissenberg-Witte, Frederik Barkhof, Bastiaan Moraal, Charlotte E. Teunissen, Theo Rispens, Bernard M. J. Uitdehaag, Joep Killestein, Zoe L. E. van Kempen
Summary: Personalized extended interval dosing of natalizumab effectively controls disease activity in multiple sclerosis and can safely extend treatment intervals through therapeutic drug monitoring.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2023)
Article
Clinical Neurology
Eva M. Strijbis, Eline Coerver, Jop Mostert, Zoe L. E. van Kempen, Joep Killestein, Jacynthe Comtois, Pavle Repovic, James D. Bowen, Gary Cutter, Marcus Koch
Summary: This study investigates the association between age and inflammatory disease activity in relapsing-remitting multiple sclerosis (RRMS) using patient-level data from randomized controlled trials (RCTs) of natalizumab treatment. The results show that older age is associated with lower prevalence and degree of focal inflammatory disease activity in treated and untreated RRMS patients. These findings provide important insights for the design of RCTs and the decision-making process of immunomodulatory treatment in RRMS.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2023)
Article
Clinical Neurology
Doriana Landi, Francesca Bovis, Alfonso Grimaldi, Pietro Osvaldo Annovazzi, Antonio Bertolotto, Alessia Bianchi, Giovanna Borriello, Vincenzo Brescia Morra, Sebastiano Bucello, Maria Chiara Buscarinu, Francesca Caleri, Marco Capobianco, Ruggero Capra, Maria Cellerino, Diego Centonze, Raffaella Cerqua, Clara Grazia Chisari, Marinella Clerico, Eleonora Cocco, Gaia Cola, Cinzia Cordioli, Erica Curti, Alessandro d'Ambrosio, Emanuele D'Amico, Giovanna De Luca, Massimiliano Di Filippo, Sonia Di Lemme, Roberta Fantozzi, Diana Ferraro, Elisabetta Ferraro, Antonio Gallo, Claudio Gasperini, Franco Granella, Matilde Inglese, Roberta Lanzillo, Lorena Lorefice, Giacomo Lus, Simona Malucchi, Monica Margoni, Giorgia Mataluni, Massimiliano Mirabella, Lucia Moiola, Carolina Gabri Nicoletti, Viviana Nociti, Francesco Patti, Federica Pinardi, Emilio Portaccio, Carlo Pozzilli, Paolo Ragonese, Sarah Rasia, Giuseppe Salemi, Elisabetta Signoriello, Francesca Vitetta, Rocco Totaro, Maria Pia Sormani, Maria Pia Amato, Girolama Alessandra Marfia
Summary: The study found that continuing natalizumab treatment throughout pregnancy and resuming it early after delivery can reduce the risk of clinical and radiological reactivation in women with multiple sclerosis. This approach has no major impact on newborns' outcomes.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2022)
Article
Clinical Neurology
Ilaria Callegari, Mika Schneider, Vera Aebischer, Margarete M. M. Voortman, Undine Proschmann, Tjalf Ziemssen, Raija Lindberg, Bettina Fischer-Barnicol, Michael Khalil, Ludwig Kappos, Jens Kuhle, Nicholas S. R. Sanderson, Tobias Derfuss
Summary: This study found that natalizumab can diffuse in different anatomical compartments, including cerebrospinal fluid and milk. By developing a flow-cytometry-based assay and applying it to quantify natalizumab in body fluids, including cerebrospinal fluid, breastmilk, and serum, a better understanding of the safety of therapeutic antibody administration during pregnancy and lactation can be achieved.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS
(2023)
Article
Clinical Neurology
Tobias Monschein, Sarinah Dekany, Tobias Zrzavy, Markus Ponleitner, Patrick Altmann, Gabriel Bsteh, Barbara Kornek, Paulus Rommer, Christian Enzinger, Franziska Di Pauli, Jorg Kraus, Thomas Berger, Fritz Leutmezer, Michael Guger
Summary: With data from the Austrian Multiple Sclerosis Therapy Registry, the effectiveness and safety of natalizumab in multiple sclerosis patients were assessed for up to 14 years. The results showed that natalizumab was effective in treating relapsing-remitting multiple sclerosis and had a favorable safety profile during long-term use.
JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Ki Hoon Kim, Su-Hyun Kim, Na Young Park, Jae-Won Hyun, Ho Jin Kim
Summary: This study evaluated the efficacy and safety of natalizumab in Korean patients with active MS, showing high efficacy in reducing annual relapse rate and improving or stabilizing disability in the majority of patients. NEDA-3 was achieved in 92% and 82% of patients at 1 and 2 years after initiating natalizumab treatment, respectively. No serious adverse events leading to discontinuation of natalizumab were observed.
FRONTIERS IN NEUROLOGY
(2021)
Article
Multidisciplinary Sciences
Simone Patergnani, Massimo Bonora, Selene Ingusci, Maurizio Previati, Saverio Marchi, Silvia Zucchini, Mariasole Perrone, Mariusz R. Wieckowski, Massimiliano Castellazzi, Maura Pugliatti, Carlotta Giorgi, Michele Simonato, Paolo Pinton
Summary: The study found that autophagy and mitophagy are increased in MS patients, with inhibitors of autophagy improving myelination and behavioral signs in experimental models of the disease, suggesting a causal role of autophagy in MS and potential therapeutic benefits of autophagy inhibitors like haloperidol and clozapine.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Article
Clinical Neurology
Peter Alping, Johan Askling, Joachim Burman, Katharina Fink, Anna Fogdell-Hahn, Martin Gunnarsson, Jan Hillert, Annette Langer-Gould, Jan Lycke, Petra Nilsson, Jonatan Salzer, Anders Svenningsson, Magnus Vrethem, Tomas Olsson, Fredrik Piehl, Thomas Frisell
ANNALS OF NEUROLOGY
(2020)
Article
Clinical Neurology
J. Salzer, G. Granasen, P. Sundstrom, M. Vagberg, A. Svenningsson
EUROPEAN JOURNAL OF NEUROLOGY
(2020)
Article
Food Science & Technology
Josefina Nystrom, Ulla-Britt Ostman, Torgny Mossing, Leif Hed, Paul Geladi
FOOD ANALYTICAL METHODS
(2020)
Article
Clinical Neurology
Anna He, Bernd Merkel, James William L. Brown, Lana Zhovits Ryerson, Ilya Kister, Charles B. Malpas, Sifat Sharmin, Dana Horakova, Eva Kubala Havrdova, Tim Spelman, Guillermo Izquierdo, Sara Eichau, Maria Trojano, Alessandra Lugaresi, Raymond Hupperts, Patrizia Sola, Diana Ferraro, Jan Lycke, Francois Grand'Maison, Alexandre Prat, Marc Girard, Pierre Duquette, Catherine Larochelle, Anders Svenningsson, Thor Petersen, Pierre Grammond, Franco Granella, Vincent Van Pesch, Roberto Bergamaschi, Christopher McGuigan, Alasdair Coles, Jan Hillert, Fredrik Piehl, Helmut Butzkueven, Tomas Kalincik
Article
Food Science & Technology
Alejandro Grimm, Josefina Nystrom, Torgny Mossing, Ulla-Britt Ostman, Paul Geladi
LWT-FOOD SCIENCE AND TECHNOLOGY
(2020)
Article
Neurosciences
Joakim Bergman, Anders Svenningsson, Per Liv, Tommy Bergenheim, Joachim Burman
FLUIDS AND BARRIERS OF THE CNS
(2020)
Article
Clinical Neurology
Joakim Bergman, Joachim Burman, Tommy Bergenheim, Anders Svenningsson
Summary: The study evaluated the effect of intrathecally delivered rituximab on PMS and found that it was well tolerated but did not halt disease progression.
JOURNAL OF NEUROLOGY
(2021)
Article
Biochemistry & Molecular Biology
Henrik Carlsson, Niclas Rollborn, Stephanie Herman, Eva Freyhult, Anders Svenningsson, Joachim Burman, Kim Kultima
Summary: This study analyzed the metabolomes of healthy individuals' CSF and identified ten metabolites significantly associated with ageing, with eight increasing with age and two decreasing with age. These findings contribute to the field of ageing metabolomics and provide motivation for further in-depth research.
Editorial Material
Clinical Neurology
Victoria M. Leavitt, Ruth Dobson, Anders Svennigsson
Article
Clinical Neurology
Tim Spelman, Melinda Magyari, Fredrik Piehl, Anders Svenningsson, Peter Vestergaard Rasmussen, Matthias Kant, Finn Sellebjerg, Hanna Joensen, Jan Hillert, Jan Lycke
Summary: This study investigated the association between national differences in treatment strategies for RRMS and disability outcomes, finding that the Swedish treatment strategy was associated with reduced rates of disability worsening compared to the Danish strategy.
Article
Clinical Neurology
Anders Svenningsson, Thomas Frisell, Joachim Burman, Jonatan Salzer, Katharina Fink, Susanna Hallberg, Joakim Hambraeus, Markus Axelsson, Faiez Al Nimer, Peter Sundstrom, Martin Gunnarsson, Rune Johansson, Johan Mellergard, Igal Rosenstein, Ahmad Ayad, Irina Sjoblom, Anette Risedal, Pierre de Flon, Eric Gilland, Jonas Lindeberg, Fadi Shawket, Fredrik Piehl, Jan Lycke
Summary: Rifund-MS study provides evidence that rituximab is superior to dimethyl fumarate in preventing relapses in patients with early relapsing-remitting multiple sclerosis. Adverse events such as infusion reactions and gastrointestinal reactions were observed, but there were no safety concerns.
Editorial Material
Clinical Neurology
Jan Lycke, Anders Svenningsson
MULTIPLE SCLEROSIS JOURNAL
(2022)
Article
Clinical Neurology
Elisa Longinetti, Hannah Bower, Kyla A. McKay, Simon Englund, Joachim Burman, Katharina Fink, Anna Fogdell-Hahn, Martin Gunnarsson, Jan Hillert, Annette Langer-Gould, Jan Lycke, Petra Nilsson, Jonatan Salzer, Anders Svenningsson, Johan Mellergard, Tomas Olsson, Fredrik Piehl, Thomas Frisell
Summary: This study investigated the risks and associations with disease-modifying therapies in multiple sclerosis patients during the COVID-19 pandemic. The results showed that multiple sclerosis patients had increased risks for COVID-19 and other severe outcomes compared to population controls, but these risk increases were not significantly different from previous years. The risk conveyed by disease-modifying therapies was smaller than previously assumed, likely due to better control for confounding factors.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY
(2022)
Article
Medicine, General & Internal
Ida Petersson, Bjorn M. Hansen, Anders Svenningsson, Annika Lundstrom
Summary: Neuroradiological findings in COVID-19 patients can resemble cerebral small vessel disease (CSVD). We present a case of a severe COVID-19 patient who showed white matter abnormalities and restricted diffusion on MRI. The patient experienced significant clinical recovery but MRI showed progression of the white matter abnormalities.
Article
Clinical Neurology
H. Tedeholm, F. Piehl, J. Lycke, J. Link, L. Stawiarz, J. Burman, P. de Flon, K. Fink, M. Gunnarsson, J. Mellergard, P. Nilsson, P. Sundstrom, A. Svenningsson, H. Johansson, O. Andersen
Summary: This study examined the impact of disease-modifying therapies (DMTs) on the risk of transition to secondary progressive MS (SPMS) using nationwide population-based data in Sweden. The results showed that the introduction of DMTs significantly decreased the incidence of SPMS conversion. The age at onset played a role in determining the risk of SPMS, and this pattern was observed in both treated and untreated subgroups.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2022)